Blocking blood flow to bone tumors may offer pain relief without major surgery
NCT ID NCT06189079
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a procedure called arterial embolization can reduce pain and improve quality of life in people with bone metastases (cancer that has spread to the bones). The procedure blocks blood flow to the tumor, which may shrink it and ease symptoms. Researchers will follow 60 participants to measure pain levels, quality of life, and tumor size changes over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- arterial embolization (a procedure that blocks blood flow to tumors)
- What this could lead to
- If successful, this could offer a low-risk way to ease pain and improve daily life for people with bone metastases that have spread from other cancers.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It is also small (60 participants) and focused on short-term symptom relief, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who underwent arterial embolization in the treatment of bone metastases
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients of either sex of age or older who are candidates for embolization therapy * Life expectancy \> 3 months * Single metastatic or oligometastatic. * Plurimetastatic if a particular site is causing painful symptoms or at risk for pathologic rupture Exclusion Criteria: * Patients with life expectancy \<3 months or severe functional status impairment (ASA 4) * Patients with hypovascular metastasis documented by angiography or MRI perfusion study with MDC. * Patients with coagulation deficiency or plateletopenic patients. * Patients with documented active infection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Istituto Ortopedico Rizzoli
RECRUITINGBologna, Emilia-Romagna, 40136, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can radiation boost a personalized prostate cancer vaccine?
- Preventive radiation may stop bone events before they start — a trial puts it to the test
- Can a new capsule ease bone metastasis pain without opioids?
- Hip muscle repair method may improve walking after bone cancer surgery
- New model aims to predict jaw bone disease before it strikes
- Could removing the primary tumor boost survival in stage IV breast cancer with Bone-Only spread?